Shilpa Medicare in Raichur has received the certificate of suitability (COS) of monograph from the European Union Directorate for Quality of Medicines (EDQM) for the active pharmaceutical ingredient, Oxaliplatin EP
Shilpa Medicare is the first company in India to bag the certificate of suitability for this product. The approval gives an opportunity for the company to penetrate into the European markets, according to the company.
The product is used for the treatment of metastatic rectal colon cancer after prior treatment with fluropyrimidines in mono-chemotherapy or associated treatment.
The world wide sales for Oxciliplatin in 2006 stood at $1.9 billion.